Brief: Ryvu Therapeutics Signs Deal With US-based Covance

Ryvu Therapeutics SA

09/03/2021 06:41

March 9 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SAID ON MONDAY IT HAS SIGNED AN AGREEMENT WITH US-BASED
COVANCE
FOR CARRYING OUT PHASE I REGARDING SAFETY AND EFFECTIVENESS OF
RVU120 (SEL120) MOLECULE ON PATIENTS WITH SOLID TUMORS
    * ESTIMATED COST OF THE AGREEMENT AMOUNTS TO 2.2 MLN EUROS

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM4p6cHWa
    
 Further company coverage:  RVU.WA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00))